References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-182-10-133-141

nogr-1462

Research Article

ДИСКУССИЯ

DISCUSSION

Ожирение и воспалительные заболевания кишечника: есть ли взаимосвязь?

Obesity and infl ammatory bowel disease: is there a link?

Бикбавова

Г. Р.

Bikbavova

G. R.

кафедра госпитальной терапии, эндокринологии, доцент, к. м. н.

улица Ленина,12, город Омск, Россия, 644099

Russia, 644099, Omsk, Russia, Lenin str., 12

galiya1976@mail.ru

https://orcid.org/0000-0002-6581-7017

Ливзан

М. А.

Livzan

M. A.

ректор, заведующая кафедрой факультетской терапии, профессиональных болезней, профессор, д. м. н.

Scopus Author ID: 24341682600 улица Ленина,12, город Омск, Россия, 644099

D. Sci. (Med.), Professor, Rector, Head of the Department of Faculty Therapy, Occupational Diseases

Scopus Author ID: 24341682600

Russia, 644099, Omsk, Russia, Lenin str., 12

Шмурыгина

Е. А.

Shmurygina

E. A.

студентка 5 курса лечебного факультета

улица Ленина,12, город Омск, Россия, 644099

5th year student of the Faculty of Medicine

Russia, 644099, Omsk, Russia, Lenin str., 12

ФГБОУ ВО «Омский государственный медицинский университет» Минздрава РоссииРоссияFederal state budgetary educational institution of higher education “Omsk State Medical University” of the Ministry of Healthcare of RussiaRussian Federation

2020

30102020

010133141

2020

Бикбавова Г.Р., Ливзан М.А., Шмурыгина Е.А.

Bikbavova G.R., Livzan M.A., Shmurygina E.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/1462

язвенный колитболезнь Кронаожирениемикробиота толстой кишкилептинадипонектин

ulcerative colitisCrohn’s diseaseobesitycolonic microbiotaleptinadiponectin

References1

Ng M., Fleming T., Robinson M., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2014, Vol. 384, no. 9945, pp. 766–781.

Дедов И. И., Мельниченко Г. А., Бутирова С. А. Жировая ткань как эндокринный орган. Ожирение и метаболизм, 2006, № .1, С. 6–13.

Dedov I. I., Melnichenko G. A., Buttirova S. A. Adipose tissue as an endocrine organ. Obesity and Metabolism. 2006, No. 1, pp. 6–13.

Ford E. S., Mokdad A. H. Epidemiology of obesity in the western hemisphere. J Clin Endocrinol Metab, 2008, Vol. 93(11 Suppl 1), pp.1–8.

Kinlen D., Cody D., O’Shea D. Complications of obesity. QJM, 2018, Vol. 111, no. 7, pp. 437–443.

Lauby-Secretan B., Scoccianti C., Loomis D., et al. Body fatness and cancer – viewpoint of the IARC working group. N Engl J Med, 2016, Vol. 375, no. 8, pp. 794–798.

Ливзан М. А., Кролевец Т. С., Лаптева И. В., Черкащенко Н. А. Неалкогольная жировая болезнь печени у лиц с абдоминальным типом ожирения. Доказательная гастроэнтерология, 2014, no. 4, С. 8–14.

Livzan M.A., Krolevets T.S., Lapteva I.V., Cherkashchenko N. A. Non-alcoholic fatty liver disease in persons with abdominal obesity. Evidence-based gastroenterology. 2014. No. 4, pp. 8–14.

Ливзан М. А., Ахмедов В. А., Кролевец Т. С. и соавт. Информативность неинвазивных маркеров фиброза печени у пациентов с неалкогольной жировой болезнью печени. Терапевтический архив, 2016, no. 12, С. 62–68.

Livzan M. A., Akhmedov V. A., Krolevets T. S. et al. Informative value of non-invasive markers of liver fibrosis in patients with non-alcoholic fatty liver disease. Therapeutic archive. 2016, No. 12, pp. 62–68.

Ng S. C, Shi H. Y, Hamidi N., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet, 2018, Vol. 390, pp. 2769–2778.

Ng S. C., Zeng Z., Niewiadomski O., et al. Early course of infl ammatory bowel disease in a population-based inception cohort study from 8 Countries in Asia and Australia. Gastroenterology, 2016, no. 150, pp. 86–95.

Ananthakrishnan A. N. Environmental risk factors for infl ammatory bowel diseases: a review. Dig. Dis. Sci, 2015, no. 60, pp. 290–298.

Бикбавова Г. Р., Ливзан М. А., Совалкин В. И. и соавт. Влияние алиментарного фактора на развитие язвенного колита. Экспериментальная и клиническая гастроэнтерология, 2019. – № 2, С. 24–27. https://doi.org/10.31146/1682–8658-ecg-162–2–24–27

Bikbavova G. R ., Livz an M. A., Sovalkin V. I., Turchaninov D. V., Tretyakova T. V., Lopatina O. E., Panova T. Yu. The effect of nutritional factors on the development of ulcerative colitis. Experimental and Clinical Gastroenterology. 2019;(2):24–27. (In Russ.) https://doi.org/10.31146/1682–8658-ecg-162–2–24–27

Kiloski N., Bret L., Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J Gastroenterol, 2008, no. 14, pp. 165–173.

Racine A., Carbonnel F., Chan S. S. M., et al. Dietary patterns and risk of inflammatory bowel disease in Europe: results from the EPIC study. Inflamm Bowel Dis, 2016, No. 22, pp. 345–354.

Ponder A., Long M. D. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol, 2013, no. 5, pp. 237–247.

Bernstein C. N., Rawsthorne P., Cheang M., Blanchard J. F. A population-based case control study of potential risk factors for IBD. Am. J. Gastroenterol. 2006, no.101, pp. 993–1002.

Lynn A. M., Harmsen W. S., Aniwan S., et al. Su1855-prevalence of obesity and influence on phenotype within a population-based cohort of infl ammatory bowel disease patients. Gastroenterology, 2018, No.154, P. 608.

Lanthier N., Leclercq I. A. Adipose tissues as endocrine target organs. Best Pract. Res. Clin. Gastroenterol, 2014, no.28, pp. 545–558.

Rosenwald M., Wolfrum C. The origin and defi nition of brite versus white and classical brown adipocytes. Adipocyte, 2014, no. 3, pp. 4–9.

Kredel L. I., Siegmund B. Adipose-tissue and intestinal inflammation – visceral obesity and creeping fat. Front. Immunol, 2014, no. 5, 462 P.

Dandona P., Aljada A., Chaudhuri A., et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and infl ammation. Circulation, 2005, no. 111, pp. 1448–1454.

Ellulu M. S., Patimah I., Khaza’ai H., et al. Obesity and inflammation: the linking mechanism and the complications. Arch. Med. Sci, 2017, no. 13, pp. 851–863.

Snekvik I., Smith C. H., Nilsen T. I.L., et al. Obesity, waist circumference, weight change and risk of incident psoriasis: prospective data from the HUNT study. J. Investig. Dermatol, 2017, no. 137, pp. 2484–2490.

Yazdanbakhsh M., van den Biggelaar A., Maizels R. M. Th2 responses without atopy: immunoregulation in chronic helminth infections and reduced allergic disease. Trends Immunol, 2001, no. 22, pp. 372–377.

Jensen C. B., Angquist L. H., Mendall M. A., et al. Childhood body mass index and risk of inflammatory bowel disease in adulthood: a population-based cohort study. Am. J. Gastroenterol, 2018, no. 113, pp. 694–701.

Melinder C., Hiyoshi A., Hussein O., et al. Physical fitness in adolescence and subsequent inflammatory bowel disease risk. Clin. Transl. Gastroenterol, 2015, no. 6, E121.

Nam S. Y. Obesity-related digestive diseases and their pathophysiology. Gut Liver, 2017, no. 11, pp. 323–334.

Bilski J., Mazur-Bialy A., Wojcik D., et al. Role of obesity, mesenteric adipose tissue and adipokines in inflammatory bowel diseases. Biomolecules, 2019, no. 9, 780 Р.

Steed H., Walsh S., Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obes. Facts, 2009, no. 2, pp. 370–372.

Genser L., Aguanno D., Soula H. A., et al. Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes. J. Pathol. 2018, no. 246, pp. 217–230.

Seminerio J. L., Koutroubakis I. E., Ramos-Rivers C., et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm. Bowel Dis, 2015, no. 21, pp. 2857–2863.

Flores A., Burstein E., Cipher D. J., Feagins L. A. Obesity in inflammatory bowel disease: a marker of less severe disease. Dig. Dis. Sci, 2015, no. 60, pp. 2436–2445.

Pringle P. L., Stewart K. O., Peloquin J. M., et al. Body mass index, genetic susceptibility and risk of complications among individuals with Crohn’s disease. Inflamm. Bowel Dis, 2015, no. 21, pp. 2304–2310.

Hu Q., Ren J., Li G., et al. The impact of obesity on the clinical course of infl ammatory bowel disease: a meta-analysis. Med. Sci. Monit, 2017, no. 23, pp. 2599–2606.

Singh S., Proudfoot J., Xu R., Sandborn W. J. Impact of obesity on short- and intermediate-term outcomes in inflammatory bowel diseases: pooled analysis of placebo arms of Infl iximab clinical trials. Inflamm. Bowel Dis, 2018, no. 24, pp. 2278–2284.

Morshedzadeh N., Rahimlou M., Asadzadeh Aghdaei H., et al. Association between adipokines levels with inflammatory bowel disease (IBD): systematic reviews. Dig. Dis. Sci, 2017, no. 62, pp. 3280–3286.

Ливзан М. А., Лаптева И. В., Кролевец Т. С. Феномен лептинорезистентности у лиц с гастроэзофагеальной рефлюксной болезнью и различными типами ожирения. Сибирский научный медицинский журнал, 2016. – Т. 36, no. 2. С. 79–85.

Livzan M. A., Lapteva I. V., Krolevets T. S. The phenomenon of leptin resistance in individuals with gastroesophageal reflux disease and various types of obesity. Siberian scientific medical journal. 2016, vol. 36, No. 2, pp. 79–85.

Francisco V., Pino J., Campos-Cabaleiro V., et al. Obesity, fat mass and immune system: role for leptin. Front. Physiol, 2018, no. 9, 640 Р.

Lord G. M, Matarese G., Howard J. K., et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998, no. 394, pp. 897–901.

Howard J. K., Lord G. M., Matarese G., et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob mice. J Clin Invest, 1999, no. 104, pp. 1051–1059.

Ozata M., Ozdemir I. C., Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab, 1999, no. 84, pp. 3686–3695.

Singh U. P., Singh N. P., Guan H., et al. The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease. Int. Rev. Immunol, 2014, no. 33, pp. 23–33.

Valentini L., Wirth, E.K., Schweizer U., et al. Circulating adipokines and the protective effects of hyperinsulinemia in infl ammatory bowel disease. Nutrition, 2009, no. 25, pp. 172–181.

Tuzun A., Uygun A., Yesilova Z., et al. Leptin levels in the acute stage of ulcerative colitis. J. Gastroenterol. Hepatol, 2004, no. 19, pp. 429–432.

Kahraman R., Calhan T., Sahin A., et al. Are adipocytokines infl ammatory or metabolic mediators in patients with inflammatory bowel disease? Ther. Clin. Risk Manag, 2017, no. 13, pp. 1295–1301.

Sitaraman S., Liu X., Charrier L., et al. Colonic leptin: source of a novel proinflammatory cytokine involved in IBD. FASEB J, 2004, no. 18, pp. 696–698.

Karmiris K., Koutroubakis I. E., Xidakis C., et al. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm. Bowel Dis, 2006, no. 12, Р. 100–105.

Waluga M., Hartleb M., Boryczka G., et al. Serum adipokines in inflammatory bowel disease. World J. Gastroenterol, 2014, no. 20, Р. 6912–6917.

Obeid S., Wankell M., Charrez B., et al. Adiponectin confers protection from acute colitis and restricts a B cell immune response. J Biol Chem, 2017, no. 292, Р. 6569–6582.

Watanabe T., Watanabe-Kominato K., Takahashi Y., et al. Adipose tissue-derived omentin-1 function and regulation. Compr. Physiol. – 2017, no. 7, Р. 765–781.

Akbarzadeh S., Nabipour I., Jafari S. M., et al. Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract, 2012, no. 95, Р. 132–138.

Hotamisligil G. S., Peraldi P., Budavari A., et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science, 1996, no. 271, Р. 665–668.

Al-Suhaimi E. A., Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur. J. Med. Res. – 2013. -Vol. 18. – P. 12.

Karmiris K., Koutroubakis I. E., Xidakis C., et al. The effect of infl iximab on circulating levels of leptin, adiponectin and resistin in patients with infl ammatory bowel disease. Eur. J. Gastroenterol. Hepatol, 2007, no. 19, Р. 789–794.

Jamaluddin M. S., Weakley S. M., Yao Q., et al. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol, 2012, no. 165, Р. 622–632.

Terzoudis S., Malliaraki N., Damilakis J., et al. Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol, 2016, no. 28, Р. 814–819.

Starr A. E., Deeke S. A., Ning Z., et al. Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn’s disease from UC. Gut, 2017, no. 66, Р. 1573–1583.

Moschen A. R., Kaser A., Enrich B., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol, 2007, no. 178, Р. 1748–1758.

Morisaki T., Takeshima F., Fukuda H., et al. High serum vaspin concentrations in patients with ulcerative colitis. Dig. Dis. Sci, 2014, no. 59, Р. 315–321.

Ohashi K., Shibata R., Murohara T., Ouchi N. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol. Metab, 2014. – № 25, Р. 348–355.

Thaiss C. A., Levy M., Grosheva I., et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science, 2018, no. 359 (6382), Р. 1376–1383.

Kriss M., Hazleton K. Z., Nusbacher N. M., et al. Low diversity gut micro- biota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol, 2018, no. 44, Р. 34–40.

Blaser M. J., Falkow S. What are the consequences of the disappearing human microbiota? Nat. Rev. Microbiol, 2009, no. 7 (12), Р. 887–894.

Gentile C. L., Weir T. L. The gut microbiota at the intersection of diet and human health. Science, 2018, no. 362, Р. 776–780.

Petersen C., Round J. L. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol, 2014, no. 16, Р. 1024–1033.

Khalili H., Chan S. S.M., Lochhead P., et al. The role of diet in the aetiopathogenesis of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol, 2018, no. 15, Р. 525–535.

Szilagyi A. Relationship(s) between obesity and inflammatory bowel diseases: possible intertwined pathogenic mechanisms. Clin J Gastroenterol, 2020, no. 13, Р. 139–152.

De Souza H. S., Fiocchi C. Immunopathogenesis of IBD: сurrent state of the art. Nat. Rev. Gastroenterol Hepatol, 2016. № 13, Р. 13–27.

Anantharaman K., Hausmann B., Jungbluth S. P., et al. Expanded diversity of microbial groups that shape the dissimilatory sulfur cycle. ISME J, 2018, no. 12, Р. 1715–1728.

Ye, C., Wang, R., Wang, M. et al. Leptin alleviates intestinal mucosal barrier injury and inflammation in obese mice with acute pancreatitis. Int J Obes, 2018, no. 42, Р. 1471–1479.

Mendall M., Harpsoe M. C., Kumar D., et al. Relation of body mass index to risk of developing inflammatory bowel disease amongst women in the Danish National Birth Cohort. PLoS ONE, 2018, no. 13. – Е0190600.

The authors declare that there are no conflicts of interest present.